10-Q/A: CDT Equity Restates Q1, Faces Going Concern Doubt

CDT Equity Inc. restated its Q1 2025 financial results due to reclassification errors, reporting increased net losses and significant liquidity concerns, while actively pursuing strategic AI partnerships and asset development.

Summary

• CDT Equity Inc. (formerly Conduit Pharmaceuticals Inc.) filed an amended Quarterly Report (10-Q/A) for the period ended March 31, 2025, restating its previously issued unaudited financial statements.
• The restatement was primarily due to the reclassification of certain milestone payments to Sarborg Limited, previously expensed as research and development, as an acquired diagnostic asset (capitalized at $0.4 million).
• The company reported a net loss of $4.753 million for the three months ended March 31, 2025, compared to a net loss of $3.552 million for the same period in 2024.
• Research and development expenses significantly increased by 616% to $0.916 million in Q1 2025 from $0.128 million in Q1 2024, driven by the Sarborg Service Agreement and Charles River MSA.
• General and administrative expenses slightly decreased by 4% to $2.7 million in Q1 2025 from $2.8 million in Q1 2024.
• Cash and cash equivalents increased to $2.130 million as of March 31, 2025, from $0.554 million as of December 31, 2024, primarily due to proceeds from the At-the-Market (ATM) program.
• The company utilized $3.929 million in cash from operating activities during Q1 2025, compared to $2.357 million in Q1 2024.
• Management has determined that there is substantial doubt about the company's ability to continue as a going concern for at least the next 12 months.
• The company is actively leveraging an ATM program, having raised $8.1 million (net of commissions) in Q1 2025, with approximately $12.0 million remaining available under the program.
• CDT Equity is focused on developing clinical assets through a novel model, acquiring and funding Phase 2-ready assets, and seeking third-party license deals post-clinical trials, leveraging AI and cybernetics.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the explicit 'going concern' warning, increased net losses, and ongoing Nasdaq listing uncertainties. While the company has a strategic vision and some cash from the ATM program, the fundamental financial health and operational control issues (restatement, ineffective disclosure controls) outweigh the positives.

Positives

• Cash and cash equivalents increased significantly to $2.130 million as of March 31, 2025, from $0.554 million at December 31, 2024, primarily due to ATM program proceeds.
• Successfully raised $8.1 million (net of commissions) through the At-the-Market (ATM) program during Q1 2025, with $12.0 million still available.
• Regained compliance with Nasdaq's Bid Price Rule as of February 26, 2025.
• Entered into a Master Services Agreement with Charles River Laboratories for preclinical testing and research services, with an initial commitment of $0.2 million.
• Secured a gain on debt extinguishment of $0.1 million from settling a convertible promissory note for $0.7 million (original value $0.8 million).
• Achieved a gain on waiver of accrued interest of $0.4 million from A.G.P. related to deferred commission payable.

Negatives

• Net loss increased to $4.753 million for the three months ended March 31, 2025, from $3.552 million for the same period in 2024.
• Accumulated deficit grew to $33.854 million as of March 31, 2025.
• Cash used in operating activities increased to $3.929 million in Q1 2025 from $2.357 million in Q1 2024.
• Management has determined that there is substantial doubt about the company's ability to continue as a going concern for at least the next 12 months.
• The company's disclosure controls and procedures were deemed not effective as of March 31, 2025, due to previously identified material weaknesses.
• Still awaiting notification from Nasdaq regarding the acceptance of its application to transfer to the Nasdaq Capital Market, despite submitting it on March 7, 2025, and believing it has demonstrated compliance with all listing rules by March 31, 2025.
• Incurred a $1.8 million loss on the change in fair value of convertible notes during Q1 2025.

Risks

• Substantial doubt about the company's ability to continue as a going concern due to significant losses and negative operating cash flows.
• Uncertainty regarding the availability of additional funding through public or private equity or debt financings on acceptable terms.
• Potential need to delay or curtail operations and research and development activities if additional funding is not secured.
• Risks common to development-stage pharmaceutical companies, including uncertainties related to pre-clinical and clinical outcomes, competitor products, and regulatory approvals.
• Dependence on key products and suppliers, and the protection of intellectual property rights.
• Risk of material adverse effect on business if license agreements, such as with AstraZeneca, are breached or terminated.
• Ongoing Nasdaq listing compliance issues, including the pending transfer to the Nasdaq Capital Market and the need to maintain Bid Price Rule compliance.
• Legal proceedings, including a $2 million claim from Strand Hanson Limited for advisory fees, with a $0.4 million liability accrued and trial scheduled for October 20, 2025.
• Intellectual property dispute with St George Street Capital claiming the company is not the sole owner of the AZD 1656 co-crystal patent, with potential for significant impact regardless of outcome.

Future Outlook

The company expects to generate operating losses and negative operating cash flows in the future and will need additional funding to support its current business plan, beyond the remaining $12.0 million from the At-the-Market offering program. Management plans to alleviate going concern doubts by pursuing additional cash resources through public or private equity or debt financings. The company intends to continue evaluating and selecting specific molecules for development, collaborating with external CROs and Key Opinion Leaders (KOLs) for clinical trials, and leveraging its AI and cybernetics platform to enhance efficiency and accelerate drug development. Following successful Phase II clinical trials, the company aims to pursue licensing opportunities with large biotech or pharmaceutical companies for upfront milestone payments and royalty income streams.

Management Comments

• Management has determined that it does not have sufficient cash and other sources of liquidity to fund its current business plan, raising substantial doubt regarding the company's ability to continue as a going concern for at least the next 12 months.
• We expect that we will commercialize any clinical assets or seek marketing approval from the FDA (or similar organizations) as we intend to enter into agreements with third parties for each such clinical asset that would provide that such third party would pursue the further development, commercialization, and marketing of such assets.
• We continue to evaluate novel artificial intelligence and cybernetics approaches to drug re-purposing, intellectual property and asset selection to give Conduit a competitive advantage.
• We intend to leverage our comprehensive clinical and scientific expertise in order to facilitate development of clinical assets through Phase II trials in an efficient manner by using CROs and third-party service providers.
• We believe that successful Phase II trials of the clinical assets in our pipeline will increase the value of our assets.
• We anticipate using any future royalty income stream to develop our asset portfolio in combination with other potential sources of financing, including debt or equity financing.
• This strategic move reaffirms Conduits commitment to adopting forward-thinking solutions to stay at the forefront of innovation in the pharmaceutical industry.

Industry Context

CDT Equity operates in the highly capital-intensive and risky clinical-stage life science sector. Its business model, focusing on acquiring and developing Phase 2-ready assets for out-licensing rather than full commercialization, represents a departure from traditional pharma/biotech. The emphasis on artificial intelligence (AI) and cybernetics for drug repurposing, discovery, and clinical trial monitoring aligns with a growing industry trend towards leveraging advanced technology to improve efficiency, reduce costs, and accelerate drug development timelines. This approach aims to differentiate the company in a competitive landscape by optimizing asset selection and development processes, potentially appealing to larger pharmaceutical companies seeking de-risked, later-stage assets.

Comparison to Industry Standards

• The company's strategy of acquiring Phase 2-ready assets and seeking out-licensing deals after successful Phase II trials is a common model for smaller biotech firms, aiming to de-risk assets before larger pharmaceutical companies take them through costly Phase III and commercialization.
• The use of AI and cybernetics, particularly through the Sarborg Service Agreement, positions CDT Equity alongside innovative industry players that are investing in digital transformation to enhance R&D efficiency, such as Recursion Pharmaceuticals or BenevolentAI, though specific comparable project results are not detailed in the filing.
• The significant increase in R&D expenses (616%) for Q1 2025, while indicative of active development, is a high burn rate typical of early-to-mid stage biotechs, but must be balanced against the company's going concern warning.
• The accumulated deficit of $33.854 million and ongoing net losses are common for clinical-stage companies that have not yet brought a product to market, but the 'substantial doubt about going concern' indicates a more severe liquidity challenge compared to industry peers with stronger cash reserves or clearer funding pathways.

Management Changes

Corporate Governance

Legal Proceedings

• Strand Hanson Limited Claim: A claim filed on September 7, 2023, in England and Wales, asserting entitlement to $2 million in advisory fees and 65,000 shares of common stock. A potential contingency of $0.4 million was accrued as of March 31, 2025, considered probable and reasonably estimable. Trial is scheduled for October 20, 2025.
• St George Street Capital IP Claim: Letters received in November and December 2024, and formal complaints filed with the Intellectual Property Office, claiming the company was not the sole owner of the AZD 1656 co-crystal patent. The company issued a counter statement in January 2025. Damages are unknown and not considered probable as of March 31, 2025, so no loss contingency was accrued.

Related Party Transactions

• Nirland: Entered into August 2024 Nirland Note ($2.7 million principal) and October 2024 Nirland Note ($0.6 million principal). Both notes were fully repaid or converted by March 31, 2025. Nirland was considered a related party due to ownership interest.
• SARBORG Limited: Entered into Sarborg Service Agreement (December 12, 2024) for algorithmic and cybernetic technology services. $0.7 million expensed as R&D, $0.4 million capitalized as an acquired diagnostic asset. Also entered into Sarborg Additional Agreement (March 31, 2025) for $2.0 million, with $1.5 million prepaid via 1,853,933 shares. Dr. Andrew Regan (CEO) sits on Sarborg's board.
• Corvus Capital Limited: Significant investor. Its principal owner, Dr. Andrew Regan, is CEO and a board member. Corvus agreed to provide certain payments and economic benefits to Nirland, potentially transferring 300,484 shares to Nirland under certain circumstances.
• A.G.P.: Financial advisor for the Merger. Issued A.G.P. Convertible Note ($5.7 million principal) for deferred commission payable. Accrued interest of $0.4 million was waived. A.G.P. also holds A.G.P. 2024 Warrants. A.G.P. is also the sales agent for the ATM program, receiving 3.0% commission.
• Officers and Directors: Certain directors received April 2024 Warrants (9,077 shares) in exchange for a lock-up agreement and $12.50 per warrant. Non-employee directors elected to receive $0.1 million in unpaid cash retainers in the form of 155,257 fully vested unregistered shares of Common Stock.

Stakeholder Impact

• Shareholders: Face significant dilution risk from ongoing ATM program and convertible note conversions. The 'going concern' warning and Nasdaq listing uncertainties pose substantial risk to share value. The share repurchase program could offer some support but is limited.
• Employees: Management changes at the CEO level and a new strategic advisory role for the former CEO indicate shifts in leadership and potentially organizational structure. Stock-based compensation is a component of employee remuneration.
• Customers/Partners (future licensees): The company's ability to secure future licensing deals depends on successful Phase II trials and resolution of IP disputes, which could impact future revenue streams.
• Creditors: Convertible note holders (like A.G.P.) have conversion options, which could reduce debt obligations but also dilute equity. Repayment of notes (Nirland) reduces immediate debt burden.
• Regulatory Authorities (SEC, Nasdaq): The restatement and identified material weaknesses in internal controls highlight compliance issues that require remediation and ongoing scrutiny.

Next Steps

• Regain and maintain ongoing compliance with Nasdaq listing rules, including the pending transfer to the Nasdaq Capital Market.
• Pursue additional cash resources through public or private equity or debt financings to fund the current business plan and address going concern issues.
• Continue development of clinical assets, including extensive preclinical and clinical testing.
• Seek third-party license deals for clinical assets following successful Phase II trials.
• Vigorously defend against the legal claim from Strand Hanson Limited (trial scheduled for October 20, 2025).
• Vigorously defend against the intellectual property claim from St George Street Capital regarding the AZD 1656 co-crystal patent.
• Implement improvements to internal control over financial reporting to remediate identified material weaknesses.

Key Dates

Recommendation

The filing presents a highly concerning financial picture. The explicit 'substantial doubt about going concern' is a severe red flag, indicating a high risk of insolvency or significant operational disruption. The company's net loss increased, and cash burn from operations remains high. While the ATM program provides some liquidity, it also implies significant future dilution. The ongoing Nasdaq listing issues and multiple legal and intellectual property disputes add layers of uncertainty and potential financial strain. The restatement of financials and identified material weaknesses in internal controls further erode confidence in financial reporting reliability. Despite strategic initiatives in AI and asset development, the immediate and severe financial and operational risks make this a 'strong sell' for any seasoned investor or institution.

Keywords

Life Sciences, Pharmaceuticals, Biotech, Clinical Stage, Drug Development, AI, Cybernetics, SEC Filing, 10-Q/A, Restatement, Going Concern, Nasdaq Listing, Intellectual Property, Convertible Notes, ATM Program, AstraZeneca, Sarborg